{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.69","value":"16.5"},{"groupId":"OG001","spread":"12.21","value":"18.1"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.45","value":"-0.9"},{"groupId":"OG001","spread":"5.16","value":"-2.9"}]}],"title":"Change at Cycle 6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"description":"Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"MEAN","populationDescription":"The PD-L1 positive population is defined as a visually-estimated combined positive score (vCPS) ≥10%; \"Overall number of participants analyzed\" refers to number of participants evaluable for this outcome measure and \"Number analyzed\" refers to participants evaluable at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline to Cycle 6 (21 days per cycle)","title":"HRQoL as Assessed by EORTC QLQ-OES18) in the PDL-1 Positive Analysis Set.","type":"SECONDARY","unitOfMeasure":"Score on a scale"}